Jobs / United States / Glaxosmithkline LLC
Executive Medical Director, Clinical Development Lead - Oncology GU
Glaxosmithkline LLC · 🇺🇸 7 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles1 certified filing for “Associate Director - Global Regulatory Affairs, Oncology” (Regulatory Affairs Managers) in WA: $154k–$154k, median $154k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029. Cancer is unrelenting, but so are we. At GSK, we are committed to transforming outcomes for people with cancer through innovative science, bold ambition, and strong partnerships across the healthcare ecosystem. We focus our science where it can matter most — advancing care in cancers with high unmet need, grounded in a deep understanding of disease biology and deliberate scientific choices that connect discovery to meaningful impact in the real world. Find out more: Our approach to R&D With GSK's growing portfolio in GU (genitourinary) cancers, we have an exciting opportunity for a Clinical Development Lead (CDL) – Oncology GU. Operating at the asset level as the enterprise clinical strategy leader, you will be accountable for defining the clinical strategy, scientific narrative, and decision framework across the asset lifecycle. The CDL serves as a full strategic partner within the Medicine Development Team (MDT) core quad, positioning Clinical Development at the centre of product strategy, governance, and investment decisions. The CDL owns the clinical roadmap and serves as the recognised clinical authority and visible leader for the asset’s strategic vision, shaping how clinical strategy, scientific insight, development innovation, and decision velocity are understood and experienced across the organisation, representing Clinical Development in both internal and external settings. You will be accountable for the strategic direction and clinical positioning of the asset, with operational study-level delivery led by Senior Scientists within the programme. This role is critical to enabling a more dynamic, data-driven, and technology-enabled model of clinical development, increasing speed, precision, and decision quality. In This Role You Will: · Define and own the clinical strategy, scientific narrative, integrated benefit–risk position, and decision framework across the asset, ensuring a coherent and differentiated clinical position throughout the lifecycle · Accountable for strategic outcomes across the asset, with study-level delivery, including design, execution, and data generation, led by Senior Scientists and programme teams within the CDL’s strategic direction · Serve as the senior clinical strategy leader on the MDT core quad, acting as a full strategic partner to the Medicine Development Leader (MDL) and representing Clinical Development in portfolio, governance, and investment decisions · Lead or co-lead governance and investment presentations to senior management, translating clinical evidence into clear strategic recommendations for portfolio prioritisation and progression · Serve as the recognised clinical authority and visible leader for the asset, ensuring its clinical vision, scientific identity, and development trajectory are clearly understood and advanced across the organisation · Drive an integrated, end-in-mind approach to development, ensuring that target selection, development pathways, regulatory positioning, and commercial readiness are considered as a connected whole · Act as the default Clinical Development representative for Health Authority interactions, advisory boards, steering committees, IDMCs, and alliance partnerships · Leverage AI-enabled insights, advanced analytics, and emerging data platforms to inform asset-level strategic decisions and drive competitive advantage in development sp